O’Neil Health Care Weekly

XLV gained 225bps last week, regaining all key moving averages including the 200-DMA ($130.77) on Friday. Support below this is the
rising 50-DMA ($128.64), while immediate resistance is at $131.92. The RS line did rally from lows, but has yet to make any
meaningful move. We still recommend an equal-to-underweight sector positioning given the lack of ideas in position to buy.

O’Neil Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq advanced 1.0% and 0.9% over four trading days, rising for a fourth consecutive week. The S&P 500 is around 1% below resistance from its July peak (4,607), while first support is the rising 10-DMA (4,505). The Nasdaq is 1.4% below July highs (14,442) and 1% above the rising 10-DMA (14,100). The distribution day count on both indices remains at one. Over the last five sessions, Health Care (+2.1%), Transportation (+1.5%) and Consumer Staple (+1.3%) are leading, while Capital Equipment (+0.5%), Utility (+0.4%), and Energy (+0.2%) are lagging.

O’Neil Health Care Weekly

XLV gained 157bps last week and is now facing resistance at its 50-DMA ($128.87). 21-DMA support is just below current prices,
followed by the next level at ~$125. Its RS line continues to decline and make new lows, which still warrants an underweight sector
positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. Both the S&P 500 and Nasdaq 100 were up more than 2% for the week, adding to gain post follow-through days two weeks prior. The S&P 500 is 3.1% above short-term support at the rising 21-DMA (4,379) as it tests resistance from the September peak (4,541). The Nasdaq is 3.9% above the rising 21-DMA (13,610) as it also tests early-September resistance (14,150). The distribution day count on both indices remains at one.

O’Neil Health Care Weekly

XLV declined 89bps last week, returning quickly back towards YTD lows after finding resistance at its rolling 50-DMA ($129.31). Its
RS line once again fell to new lows, still warranting an underweight sector positioning. SWAV and INSP breaking down post print
combined with further positive GLP-1 news from LLY resulted in multiple individual groups breaking lower including Biotech (XBI),
Equipment (XHE), Med Tech (IHI), Services (XHS), and Small Caps (PSCH). Ideas holding up despite poor sector performance
include CAH, COR, MCK, AMPH, LLY, NVO, VRTX, CNC, MOH, UNH, ICLR, MEDP, and ITGR.

Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq continue to consolidate constructively above their 50-DMA (S&P 500: 4,338, Nasdaq: 13,401) support despite each index picking up a distribution day in the process. Indices jumped higher on Friday, as the Nasdaq has regained and is attempting to hold above its 100-DMA (13,618) while the S&P 500 is testing 100-DMA (4,403) resistance.

O’Neil Health Care Weekly

XLV rose 3.47% last week, narrowly closing back above its 10- and 21-DMA ($127.35). The next level of major resistance is the rolling
50-DMA ($130), followed by the 200-DMA ($131). Though XLV rallied from YTD lows last week, its RS line made a lower low as few
constituents kept up with the broader market bounce. Overall, we continue to recommend an underweight sector positioning, until
the index regains key resistance, RS improves, and more ideas move up on their right sides.

Market View

The U.S. market was upgraded to a Confirmed Uptrend. The S&P 500 and Nasdaq each staged a follow-through day this week and remain under heavy accumulation. Each index has cleared multiple levels of resistance including its 50-DMA ( S&P 500: 4,348; Nasdaq: 13,425), which now is a level of short-term support. The next level of resistance is near the 100-DMA (S&P 500: 4,403; Nasdaq: 13,620).

O’Neil Health Care Weekly

XLV declined 3.8% last week, breaking to year-to-date lows. The next level of support below current levels is ~$120. Its RS line
remains rangebound, warranting an equal to underweight sector positioning. Along with XLV, the majority of Health Care industry
groups are trading at year-to-date or multi-year lows, including Equipment (XHE), Biotech (XBI), Pharma (PPH), Medical Devices
(IHI), Services (XHS), and Small Caps (PSCH).

Market View

The U.S. market remains in a Downtrend. The S&P 500 and Nasdaq declined 2.5% and 2.6%, respectively, for the week. Both breached early-October lows, which had held for the prior three weeks. The S&P 500 faces resistance at the 200-DMA and has support near ~4,050 level (-1%), or the lows of the April/May consolidation. The Nasdaq breached its 200-DMA for the first time since March and now has immediate support at ~12,270 level (-3%). The Nasdaq could generate a follow-through day as early as Wednesday if the 12,544 low from this week holds.